Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 304801 in severe or uncontrolled hypertriglyceridemia
NCT01529424Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Jan 2014
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of volanesorsen in hypertriglyceridemia (5 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Very Low Density Lipoprotein Apolipoprotein C-III at 92 days. Started Feb 2012; status: completed.
02
Drugs
volanesorsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01529424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529424.